Exact Sciences - EXAS Stock Forecast, Price & News

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Evercore ISI lifted their price objective on shares of Exact Sciences to $65.00 in a report on Tuesday, August 9th. Piper Sandler assumed coverage on shares of Exact Sciences in a report on Thursday, June 2nd. They issued a "neutral" rating and a $50.00 price objective for the company. The Goldman Sachs Group cut their price objective on shares of Exact Sciences from $100.00 to $85.00 and set a "buy" rating for the company in a report on Tuesday, April 19th. Cowen cut their price objective on shares of Exact Sciences from $83.00 to $67.00 and set an "outperform" rating for the company in a report on Wednesday, August 3rd. Finally, Craig Hallum cut their price objective on shares of Exact Sciences from $81.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, August 3rd. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $71.00.

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $44.24 on Tuesday. The company's 50-day moving average is $43.91 and its two-hundred day moving average is $57.62. The firm has a market capitalization of $7.83 billion, a price-to-earnings ratio of -10.46 and a beta of 1.32. Exact Sciences has a 1-year low of $35.34 and a 1-year high of $108.99. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.48 and a quick ratio of 2.23.

Insider Activity

In related news, Director Katherine S. Zanotti sold 4,608 shares of the company's stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total transaction of $208,005.12. Following the sale, the director now directly owns 60,318 shares of the company's stock, valued at approximately $2,722,754.52. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Katherine S. Zanotti sold 4,608 shares of the company's stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total transaction of $208,005.12. Following the sale, the director now directly owns 60,318 shares of the company's stock, valued at approximately $2,722,754.52. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Katherine S. Zanotti sold 1,086 shares of the company's stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $40.13, for a total transaction of $43,581.18. Following the sale, the director now directly owns 60,318 shares in the company, valued at $2,420,561.34. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,701 shares of company stock valued at $251,872. Company insiders own 1.30% of the company's stock.